Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Stelis Biopharma
Stelis Biopharma
Activities:
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Stelis Biopharma appoints Mark W. Womack as CEO
Before joining Stelis, Womack was the Chief Business Officer for AGC Biologics
Manufacturing
RDIF and Stelis partner to supply Sputnik V vaccine doses
The agreement covers 200 million doses of the Sputnik V vaccine, which is enough to vaccinate 100 million individuals
Finance
Stelis starts next phase of facility investment
This phase will see the company start work on installing two 2,000L single-use bioreactor trains in its mammalian CGMP facility
Manufacturing
Stelis Biopharma begins construction of US$60m multiproduct biologics facility in Malaysia
Will incorporate the latest single-use bioreactor systems for scale-up and process development
Subscribe now